CNCE Stock Summary

• CNCE's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1.1 -- higher than merely 7.33% of US-listed equities with positive expected earnings growth.
• With a price/sales ratio of 6,316.87, Concert Pharmaceuticals Inc has a higher such ratio than 99.95% of stocks in our set.
• As for revenue growth, note that CNCE's revenue has grown -99.98% over the past 12 months; that beats the revenue growth of just 0.54% of US companies in our set.
• Stocks with similar financial metrics, market capitalization, and price volatility to Concert Pharmaceuticals Inc are SAGE, VHC, TGTX, ZYNE, and NK.
• Visit CNCE's SEC page to see the company's official filings. To visit the company's web site, go to www.concertpharma.com.